A Virtual Reality Tour – The Role of Risk Evaluation in Minimizing Recurrence and Metastasis in Patients with cSCC Undergoing Surgical Intervention

FACULTY

Nikhil I. Khushalani, MD
Vice Chair and Senior Member, Cutaneous Oncology
Chief, Medical Oncology
Moffitt Cancer Center
Tampa, FL

PROGRAM OVERVIEW

This enduring activity is focused on the management of patients with advanced or metastatic cutaneous squamous cell carcinoma.

TARGET AUDIENCE

This activity is designed to meet the educational needs of surgical dermatologists, Mohs surgeons, surgical oncologists, dermatologists, and other healthcare practitioners who care for patients with advanced or metastatic cutaneous squamous cell carcinoma.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Compare the relative effectiveness of tumor staging systems for the identification of patients with cutaneous squamous cell carcinoma (cSCC) at high-risk of recurrence or metastasis
  • Utilize tumor staging and risk evaluation to stratify candidates for Mohs micrographic surgery, standard excision, or nonsurgical interventions and discuss the benefits and risks of each therapeutic option
  • Evaluate guidelines for surgical and pharmacologic treatment of cSCC based on clinical trial data
  • Identify patients with unresectable cSCC who would benefit from targeted systemic therapy

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 0.25 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with advanced or metastatic cutaneous squamous cell carcinoma.
CNE Credits: 0.25 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 0.25 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY

Nikhil I Khushalani, MD, discloses that he has received research funding (Institute) from BMS, Merck, Amgen, GSK, HUYA, Regeneron, Novartis, Celgene. He is on the Advisory Boards/has received honoraria from HUYA, BMS, EMD Serono, Genentech, Regeneron, Immunocore, Merck, Sanofi. He is on the Data Safety Monitoring Board for AstraZeneca and Incyte. Dr. Khushalani owns stock in TransEnterix, Bellicum, and Amarin Corporation.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Melissa A Johnson, Sr. Program Manager of Med Learning Group, has nothing to disclose.
Marcello A. Morgan, MD, MPH, Medical Director of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate after the web-based live activity.

NOTE: Cemiplimab is currently the only FDA-approved immunotherapy for cSCC, but other therapies used off-label are discussed in the activity.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: June 12, 2020

EXPIRATION DATE: June 12, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.